TY - JOUR
T1 - Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients
AU - Platanias, Leonidas C.
AU - Miller, Carole B.
AU - Mick, Rosemarie
AU - Hart, Ronald D.
AU - Ozer, Howard
AU - McEvilly, Jan Marie
AU - Jones, Richard J.
AU - Ratain, Mark J.
PY - 1991/11
Y1 - 1991/11
N2 - Thirty patients with chemotherapy-induced anemia were treated with recombinant human erythropoietin for 4 weeks. In this dose-escalation study, cohorts of five to eight patients were treated per dose level. The doses of erythropoietin were 25, 50, 100, 200, or 300 IU/kg/d given intravenously for 5 days each week. Of 30 patients, 15 (50%) had a greater than 10% increase of their hemoglobin (Hb) values and were considered responders. At the two highest dose levels, 11 of 13 patients (85%) responded. In the 15 responding patients, the mean Hb level increased by 1.7 g/dL from baseline compared with an average decrease of 1.5 g/dL in the previous cycles of chemotherapy without erythropoietin administration. Recombinant human erythropoietin is effective in ameliorating chemotherapy-induced anemia when administered in adequate doses.
AB - Thirty patients with chemotherapy-induced anemia were treated with recombinant human erythropoietin for 4 weeks. In this dose-escalation study, cohorts of five to eight patients were treated per dose level. The doses of erythropoietin were 25, 50, 100, 200, or 300 IU/kg/d given intravenously for 5 days each week. Of 30 patients, 15 (50%) had a greater than 10% increase of their hemoglobin (Hb) values and were considered responders. At the two highest dose levels, 11 of 13 patients (85%) responded. In the 15 responding patients, the mean Hb level increased by 1.7 g/dL from baseline compared with an average decrease of 1.5 g/dL in the previous cycles of chemotherapy without erythropoietin administration. Recombinant human erythropoietin is effective in ameliorating chemotherapy-induced anemia when administered in adequate doses.
UR - http://www.scopus.com/inward/record.url?scp=0025951612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025951612&partnerID=8YFLogxK
U2 - 10.1200/JCO.1991.9.11.2021
DO - 10.1200/JCO.1991.9.11.2021
M3 - Article
C2 - 1941061
AN - SCOPUS:0025951612
SN - 0732-183X
VL - 9
SP - 2021
EP - 2026
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 11
ER -